Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Montreal, CAN
201 President-Kennedy Ave
Suite PK-R220, Quebec,
Montreal, H2X 3Y7, CAN

Funding

TOTAL $6.81M
FUNDING TOTAL $6.81M
Venture Round, 1/2005
BDC Venture Capital
$807k
Venture Round, 12/2005
BDC Venture Capital
VIMAC Milestone Medical Fund
$6M

Tags

AngioChem

AngioChem is a clinical-stage biotechnology discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. Their EPiC platform solves the key problem for crossing the blood-brain barrier by developing novel drugs that use a receptor-based approach. These novel Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.

Recent Milestones

Videos

Screenshots

AngioChem screenshot
Above: AngioChem
Uploaded: 8/28/10

Sources

  1. EDGAR [edit]
  2. AngioChem Completes a $6 Million Financing to Advance CNS Drug Development (angiochem.com) [edit]
Edit This Page
Last Edited 4/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy